BR112017020002A2 - COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT - Google Patents

COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT

Info

Publication number: BR112017020002A2
Authority: BR; Brazil
Prior art keywords: antibody; entinostat; cancer; patient; administered
Prior art date: 2015-03-20

Application number

BR112017020002-3A

Other languages

English (en)

Portuguese (pt)

Inventor

Goodenow Robert

Ordentlich Peter

Original Assignee

Syndax Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-20

Filing date

2016-03-18

Publication date

2018-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56977796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020002(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-18 Application filed by Syndax Pharmaceuticals, Inc. filed Critical Syndax Pharmaceuticals, Inc.

2018-06-19 Publication of BR112017020002A2 publication Critical patent/BR112017020002A2/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

BR112017020002-3A 2015-03-20 2016-03-18 COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT BR112017020002A2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562136303P	2015-03-20	2015-03-20
US62/136,303		2015-03-20
US201562137601P	2015-03-24	2015-03-24
US62/137,601		2015-03-24
PCT/US2016/023298 WO2016154068A1 (en)	2015-03-20	2016-03-18	Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (1)

Publication Number	Publication Date
BR112017020002A2 true BR112017020002A2 (en)	2018-06-19

Family

ID=56977796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112017020002-3A BR112017020002A2 (en)	2015-03-20	2016-03-18	COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT

Country Status (11)

Country	Link
US (3)	US11324822B2 (2)
EP (1)	EP3270966B1 (2)
JP (3)	JP2018508593A (2)
KR (1)	KR20170124604A (2)
CN (1)	CN107614011A (2)
AU (2)	AU2016235434B2 (2)
BR (1)	BR112017020002A2 (2)
ES (1)	ES2986548T3 (2)
IL (3)	IL254529B2 (2)
MX (1)	MX2017012113A (2)
WO (1)	WO2016154068A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
AU2016318136B2 (en)	2015-09-02	2022-10-20	Syndax Pharmaceuticals, Inc.	Selection of patients for combination therapy
US20190183870A1 (en) *	2016-01-05	2019-06-20	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Combination of histone deacetylase inhibitor and immunotherapy
RU2018130831A (ru)	2016-01-28	2020-03-02	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11497746B2 (en)	2016-11-23	2022-11-15	Acetylon Pharmaceuticals, Inc.	Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof
WO2018213665A1 (en)	2017-05-19	2018-11-22	Syndax Pharmaceuticals, Inc.	Combination therapies
KR20200051712A (ko) *	2017-09-08	2020-05-13	4에스체 악티엔게젤샤프트	암 치료를 위한 면역 체크포인트 조절제와 조합된 hdac 억제제
US20210024633A1 (en) *	2018-03-28	2021-01-28	Ensemble Group Holdings	Methods of treating cancer in subjects having dysregulated lymphatic systems
AU2019266231B2 (en) *	2018-05-07	2025-08-21	Syndax Pharmaceuticals, Inc.	Selection of patients for combination therapy
AU2019285640A1 (en)	2018-06-15	2021-01-21	Board Of Regents Of The University Of Texas System	Methods of treating and preventing breast cancer with S-equol
WO2019240872A1 (en) *	2018-06-15	2019-12-19	The Board Of Regents Of The University Of Texas System	Methods of treating and preventing melanoma with s-equol
KR20210028339A (ko) *	2019-09-04	2021-03-12	크리스탈지노믹스(주)	Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
WO2021129616A1 (zh) *	2019-12-23	2021-07-01	信达生物制药(苏州)有限公司	抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
WO2024222705A1 (zh) *	2023-04-25	2024-10-31	深圳微芯生物科技股份有限公司	用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
US20240382463A1 (en) *	2023-05-18	2024-11-21	Avstera Therapeutics Corp.	Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same
US12553903B2 (en)	2023-06-01	2026-02-17	Cg Pharmaceuticals, Inc	Ivaltinostat combination therapy for treating pancreatic cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4328245A (en)	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4410545A (en)	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4409239A (en)	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en)	1998-02-10	2002-02-26	Generex Pharmaceuticals Incorporated	Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en)	2011-12-09	2013-06-13	Syndax Pharmaceuticals, Inc.	Methods for the treatment of lung cancer
US8987067B2 (en) *	2013-03-01	2015-03-24	International Business Machines Corporation	Segmented guard ring structures with electrically insulated gap structures and design structures thereof
CA2917858A1 (en) *	2013-08-02	2015-02-05	Aduro Biotech Holdings, Europe B.V.	Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) *	2013-09-05	2015-03-12	The Johns Hopkins University	Cancer therapy via a combination of epigenetic modulation and immune modulation
US9987258B2 (en) *	2014-04-06	2018-06-05	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Histone deacetylase as a modulator of PDL1 expression and activity
US10869926B2 (en) *	2014-07-15	2020-12-22	The Johns Hopkins University	Suppression of myeloid derived suppressor cells and immune checkpoint blockade
TWI716362B (zh) *	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
US20180353602A1 (en) *	2015-06-29	2018-12-13	Syndax Pharmaceuticals, Inc.	Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
AU2016318136B2 (en) *	2015-09-02	2022-10-20	Syndax Pharmaceuticals, Inc.	Selection of patients for combination therapy

2016
- 2016-03-18 JP JP2018500281A patent/JP2018508593A/ja active Pending
- 2016-03-18 IL IL254529A patent/IL254529B2/en unknown
- 2016-03-18 CN CN201680028952.1A patent/CN107614011A/zh active Pending
- 2016-03-18 MX MX2017012113A patent/MX2017012113A/es unknown
- 2016-03-18 EP EP16769460.3A patent/EP3270966B1/en not_active Revoked
- 2016-03-18 IL IL323063A patent/IL323063A/en unknown
- 2016-03-18 IL IL307850A patent/IL307850A/en unknown
- 2016-03-18 BR BR112017020002-3A patent/BR112017020002A2/en not_active Application Discontinuation
- 2016-03-18 US US15/559,402 patent/US11324822B2/en active Active
- 2016-03-18 WO PCT/US2016/023298 patent/WO2016154068A1/en not_active Ceased
- 2016-03-18 ES ES16769460T patent/ES2986548T3/es active Active
- 2016-03-18 KR KR1020177030064A patent/KR20170124604A/ko not_active Ceased
- 2016-03-18 AU AU2016235434A patent/AU2016235434B2/en active Active
2021
- 2021-08-10 JP JP2021130582A patent/JP7540980B2/ja active Active
2022
- 2022-04-08 US US17/716,547 patent/US20230022573A1/en not_active Abandoned
- 2022-05-03 AU AU2022202954A patent/AU2022202954A1/en not_active Abandoned
2024
- 2024-04-26 JP JP2024072421A patent/JP2024091945A/ja active Pending
- 2024-08-08 US US18/797,933 patent/US20240398944A1/en active Pending

Also Published As

Publication number	Publication date
JP2024091945A (ja)	2024-07-05
KR20170124604A (ko)	2017-11-10
US20180078639A1 (en)	2018-03-22
US20230022573A1 (en)	2023-01-26
NZ735686A (en)	2024-07-26
IL323063A (en)	2025-10-01
AU2022202954A1 (en)	2022-05-26
IL254529B2 (en)	2024-05-01
JP7540980B2 (ja)	2024-08-27
JP2018508593A (ja)	2018-03-29
IL307850A (en)	2023-12-01
AU2016235434B2 (en)	2022-02-03
US11324822B2 (en)	2022-05-10
US20240398944A1 (en)	2024-12-05
EP3270966B1 (en)	2024-05-01
HK1250142A1 (en)	2018-11-30
EP3270966A4 (en)	2018-10-17
EP3270966A1 (en)	2018-01-24
AU2016235434A1 (en)	2017-10-12
ES2986548T3 (es)	2024-11-11
CN107614011A (zh)	2018-01-19
MX2017012113A (es)	2018-07-06
JP2021175754A (ja)	2021-11-04
RU2017134315A (ru)	2019-04-03
WO2016154068A1 (en)	2016-09-29
CA2980297A1 (en)	2016-09-29
RU2017134315A3 (2)	2019-09-12
IL254529B1 (en)	2024-01-01
IL254529A0 (en)	2017-11-30

Legal Events

Date	Code	Title	Description
2019-07-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-09-08	B07G	Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]	Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021
2021-09-21	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2024-10-29	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2025-02-25	B09B	Patent application refused [chapter 9.2 patent gazette]

Publication	Publication Date	Title
JP7540980B2 (ja)	2024-08-27	がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
EP3313433A1 (en)	2018-05-02	Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US11397184B2 (en)	2022-07-26	Selection of patients for combination therapy
JP2018538321A (ja)	2018-12-27	卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
CA2980297C (en)	2025-08-12	Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
AU2019266231B2 (en)	2025-08-21	Selection of patients for combination therapy
RU2796903C2 (ru)	2023-05-29	Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
HK1250142B (en)	2024-11-29	Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine
HK40096805A (zh)	2024-03-01	用於组合疗法的患者的选择